Insider Sale Overview
Michael Schmertzler, a director of PTC Therapeutics Inc., sold a total of 20,000 shares of the company’s common stock on September 16 and 17 2026. The sales were conducted under a Rule 10b5‑1 trading plan adopted by Section Six Partners, L.P. on May 14 2026. On September 16, he sold 2,994 shares at a weighted average price of $66.58 (range $65.99‑$66.96) and an additional 7,006 shares at $67.35 average (range $66.99‑$67.72). On September 17, he sold 9,624 shares at $67.83 average (range $67.27‑$68.10) and a final block of 376 shares at $68.45 average (range $68.35‑$68.84). The aggregate proceeds amounted to approximately $1,349,727.
Ownership Post‑Sale
Following the transactions, Schmertzler’s indirect beneficial ownership through Section Six Partners, L.P. stands at 1,296,594 shares of PTC Therapeutics common stock. He disclaims any beneficial ownership of these shares except to the extent of his pecuniary interest.
Recent Financial Performance
In the same period, PTC Therapeutics announced its second‑quarter 2026 results, delivering earnings of $0.92 per share on revenue of $361 million, well above analysts’ expectations of $0.32 EPS and $293.1 million sales. The company highlighted record revenue from its product Sephience, raised its full‑year revenue outlook, and reported a cash balance of $2.23 billion, providing flexibility for future investments and potential transactions.
Market Context
Macquarie reported that global biotech funding increased 75 percent year‑over‑year, with initial public offerings rising 224 percent and follow‑on offerings up 140 percent, underscoring a robust financing environment for biotech firms such as PTC Therapeutics.